Breaks Categories: News

ThursdayMay 15, 2025 12:38 pm

BioMedNewsBreaks — Intelligent Bio Solutions Inc. (NASDAQ: INBS) Surpasses 450 Accounts as Fingerprint Drug Testing Expands Globally

Intelligent Bio Solutions (NASDAQ: INBS)  reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations. These milestones support the company’s global expansion strategy and position it for entry into the multi-billion-dollar U.S. testing market.  To view the full article, visit https://ibn.fm/G4LCD  About Intelligent Bio Solutions Inc.  Intelligent Bio Solutions Inc.…

Continue Reading

ThursdayMay 15, 2025 12:30 pm

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE…

Continue Reading

ThursdayMay 15, 2025 12:14 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses

Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers.  To view the full press release, visit: https://ibn.fm/LsYFS  About Calidi Biotherapeutics  Calidi Biotherapeutics…

Continue Reading

ThursdayMay 15, 2025 9:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q1 Revenue of $14.5M, Expands Airtime Business Despite Healthcare Headwinds

NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with $17.7 million in cash and expanded its e-Commerce reach, including a 51% increase in recurring airtime revenue and growing OPKO product sales in China. Management remains focused on high-margin services and strategic healthcare growth. To…

Continue Reading

WednesdayMay 14, 2025 3:40 pm

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).  The earnings update comes shortly after news that NRx’s wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is…

Continue Reading

WednesdayMay 14, 2025 9:30 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update

HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans. To view the full press release, visit https://ibn.fm/lY3uZ About HeartBeam Inc. HeartBeam is a medical technology company dedicated to…

Continue Reading

WednesdayMay 14, 2025 9:15 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14,…

Continue Reading

TuesdayMay 13, 2025 9:30 am

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (Nasdaq: INBS) Grows Revenue, Cuts Losses in Fiscal Q3 as Cartridge Sales Drive Margins

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential revenue increase to $728,867 in fiscal Q3 2025, driven by growth in cartridge sales, which now account for 58% of total revenue and strengthen its recurring revenue model. Gross profit surged 91% year-over-year to $341,368, while net loss narrowed by $434,141 to $2.54 million. INBS added 35 new accounts, bringing its active customer base to over 450, and continued expanding internationally through partnerships and multilingual system upgrades. The company also secured its sixth U.S. patent and advanced regulatory efforts across key global…

Continue Reading

TuesdayMay 13, 2025 9:20 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval. To view the full press release, visit https://ibn.fm/5EscL About…

Continue Reading

TuesdayMay 13, 2025 9:00 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject…

Continue Reading